...
首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Nanomedicine: Interaction of biomimetic apatite colloidal nanoparticles with human blood components
【24h】

Nanomedicine: Interaction of biomimetic apatite colloidal nanoparticles with human blood components

机译:纳米药物:仿生磷灰石胶体纳米颗粒与人体血液成分的相互作用

获取原文
获取原文并翻译 | 示例
           

摘要

This contribution investigates the interaction of two types of biomimetic-apatite colloidal nanoparticles (negatively-charged 47 nm, and positively-charged 190 nm NPs) with blood components, namely red blood cells (RBC) and plasma proteins, with the view to inspect their hemocompatibility. The NPs, preliminarily characterized by XRD, FTIR and DLS, showed low hemolysis ratio (typically lower than 5%) illustrating the high compatibility of such NPs with respect to RBC, even at high concentration (up to 10 mg/ml). The presence of glucose as water-soluble matrix for freeze-dried and re-dispersed colloids led to slightly increased hemolysis as compared to glucose-free formulations. NPs/plasma protein interaction was then followed, via non-specific protein fluorescence quenching assays, by contact with whole human blood plasma. The amount of plasma proteins in interaction with the NPs was evaluated experimentally, and the data were fitted with the Hill plot and Stern-Volmer models. In all cases, binding constants of the order of 10(1)-10(2) were found. These values, significantly lower than those reported for other types of nanoparticles or molecular interactions, illustrate the fairly inert character of these colloidal NPs with respect to plasma proteins, which is desirable for circulating injectable suspensions. Results were discussed in relation with particle surface charge and mean particle hydrodynamic diameter (HD). On the basis of these hemocompatibility data, this study significantly complements previous results relative to the development and nontoxicity of biomimetic-apatite-based colloids stabilized by non-drug biocompatible organic molecules, intended for use in nanomedicine. (C) 2016 Elsevier B.V. All rights reserved.
机译:该贡献调查了两种类型的仿生磷灰石胶体纳米颗粒(带负电的47 nm和带正电的190 nm NP)与血液成分(即红细胞(RBC)和血浆蛋白)的相互作用,以检查它们的相互作用。血液相容性。初步由XRD,FTIR和DLS表征的NPs溶血率低(通常低于5%),说明即使在高浓度(最高10 mg / ml)下,这些NPs与RBC的相容性也很高。与不含葡萄糖的制剂相比,葡萄糖作为冷冻干燥和再分散的胶体的水溶性基质的存在导致溶血略有增加。然后,通过非特异性蛋白质荧光猝灭测定,通过与整个人血浆接触来跟踪NP /血浆蛋白相互作用。实验评估了与NP相互作用的血浆蛋白的量,并将数据与Hill图和Stern-Volmer模型拟合。在所有情况下,发现的结合常数约为10(1)-10(2)。这些值显着低于其他类型的纳米颗粒或分子相互作用的报道值,说明这些胶体NP对血浆蛋白具有相当惰性的特性,这对于循环注射悬浮液是理想的。讨论了有关颗粒表面电荷和平均颗粒流体动力学直径(HD)的结果。在这些血液相容性数据的基础上,本研究对以前的结果进行了补充,该结果与旨在用于纳米药物的非药物生物相容性有机分子稳定的仿生磷灰石基胶体的发展和无毒有关。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号